New Pancreatic Cancer Drug an FDA Priority

New Pancreatic Cancer Drug an FDA Priority

The FDA has granted Celgene's abraxane priority review as a first-line treatment for advanced pancreatic cancer, a move that shortens the normal review period by four months. In this video, health-care analyst David Williamson discusses what these

6
Like
Save

Comments

Write a comment

*